natgillin/translations-raw huggingface dataset:
Number of enterprises in the gross sample and in the effective sample.
Razpredelnice, ki jih je treba predložiti za opazovani efektivni vzorec (razčlenjene po skupinah dejavnosti NACE Rev.
Tables to be provided for the observed effective sample (broken down by NACE Rev. 2 and size classes according to the national sampling plan):
2 in velikostnih razredih skladno z nacionalnim načrtom vzorčenja):
Coefficients of variation [2] for the following key statistics.
Koeficienti variacije [2] za naslednje ključne statistične podatke:
Total number of persons employed, total number of enterprises that provided any form of CVT, ratio of the total number of enterprises that provided any form of CVT to the total number of enterprises.
Skupno število zaposlenih, skupno število podjetij, ki so zagotovila kakršno koli NPU, razmerje med skupnim številom podjetij, ki so zagotovila NPU, in skupnim številom podjetij.
Total number of persons employed in enterprises that provided any form of CVT, total number of participants in CVT courses, ratio of the total number of participants in CVT courses to the total number of persons employed, ratio of the total number of participants in CVT courses to the total number of persons employed in enterprises that provided CVT.
Skupno število zaposlenih v podjetjih, ki so zagotovila kakršno koli obliko NPU, skupno število udeležencev tečajev NPU, razmerje med skupnim številom udeležencev tečajev NPU in skupnim številom zaposlenih, razmerje med skupnim številom udeležencev tečajev NPU in skupnim številom zaposlenih v podjetjih, ki so zagotovila NPU.
Total number of enterprises providing IVT, ratio of the total number of enterprises providing IVT to the total number of enterprises.
Skupno število podjetij, ki zagotavljajo ZPU, razmerje med skupnim številom podjetij, ki so zagotovila tečaje ZPU, in skupnim številom podjetij.
Description of the register used for sampling and its overall quality, information included in the register, and its updating frequency.
Opis registra, uporabljenega za vzorčenje, in njegove splošne kakovosti, podatke, vsebovane v registru, in pogostnost posodabljanja registra.
Where appropriate an assessment of errors that occurred at the stage of data collection due to:
Po potrebi ocena napak, ki so se zgodile pri zbiranju podatkov zaradi:
The questionnaire design (results of pre-tests or laboratory methods; questioning strategies).
oblike vprašalnika (rezultati predhodnih testiranj ali laboratorijske metode; strategije spraševanja),
Reporting unit/respondent considering the data collection mode used (e.g. problems and strategies to find the appropriate respondent(s) in the enterprise, memory problems, errors when filling the forms, assistance to the respondent).
poročevalskih enot/poročevalcev glede na uporabljeni način zbiranja podatkov (npr. težave in strategije pri iskanju ustreznih poročevalcev v podjetju, spominske težave, težave pri izpolnjevanju obrazcev, pomoč poročevalcu).
This includes a description and assessment of measures taken to ensure the high quality of the information related to “participants” and to assure that “participant events” were not collected.
To vključuje opis in oceno ukrepov za zagotovitev visoke kakovosti informacij o ‚udeležencih‘ ter za zagotovitev, da se ne zbirajo podatki o ‚usposabljanjih udeležencev‘,
Existence/use of relevant information systems and administrative records in the enterprise, e.g. correspondence between the administrative and survey concept (reference period, availability of individual data).
obstoja/uporabe ustreznih informacijskih sistemov in administrativnih evidenc v podjetju, npr. ujemanje med administrativnim konceptom in konceptom raziskovanja (referenčno obdobje, razpoložljivost posameznih podatkov),
Methods used to reduce this kind of errors, problems with the questionnaire as a whole or with single questions.
metod zmanjševanja takšnih napak, težav z vprašalnikom v celoti ali s posameznimi vprašanji.
This covers a description of the data editing process such as processing system and tools used, errors due to coding, editing, weighting or tabulation, quality checks at macro/micro level and corrections/failed edits.
To vključuje opis urejanja podatkov, na primer sistem obdelave in uporabljena orodja, napake zaradi kodiranja, urejanja, ponderiranja ali razpredelnic, preverjanje kakovosti na makro/mikro ravni ter popravke/neuspelo urejanje.
Report on imputation procedures including methods used for imputation and/or re-weighting.
poročilo o postopku imputiranja, vključno z metodami, ki se uporabljajo za imputiranje in/ali ponovno ponderiranje,
Methodological notes and results of non-response analysis or other methods to assess the effects of non-response.
metodološke opombe in rezultate analize neodgovorov ali druge metode ocenjevanja vpliva neodgovorov.
Unit response rates [3].
deleži odgovorov enot [3],
Item response rates [4] for the following with respect to all respondents:
deleži odgovorov spremenljivk [4] za naslednji spremenljivki glede na vse poročevalce:
total number of hours worked for all respondents and total labour cost for all respondents.
skupno število opravljenih delovnih ur vseh poročevalcev in skupni stroški dela vseh poročevalcev,
Item response rates for the following with respect to enterprises offering CVT courses:
deleži odgovorov spremenljivk za spodnje spremenljivke glede na podjetja, ki zagotavljajo tečaje NPU:
Total number of participants in CVT courses for enterprises offering CVT courses.
skupno število udeležencev tečajev NPU za podjetja, ki zagotavljajo tečaje NPU,
Total number of hours of all CVT courses for enterprises offering CVT courses, number of hours of internal CVT for enterprises offering CVT courses, number of hours of external CVT for enterprises offering CVT courses.
skupno število ur vseh tečajev NPU za podjetja, ki zagotavljajo tečaje NPU, število ur notranjega NPU za podjetja, ki zagotavljajo tečaje NPU, število ur zunanjega NPU za podjetja, ki zagotavljajo tečaje NPU,
Total costs of CVT courses for enterprises offering CVT courses.
skupni stroški tečajev NPU za podjetja, ki zagotavljajo tečaje NPU.
This covers a table of dates when different phases of the project started and ended such as fieldwork (considering the different data collection modes), reminders and follow-up, data checking and editing, further validation and imputation, non-response survey (as appropriate) and estimations as well as data transmission to Eurostat and dissemination of national results.
To vključuje razpredelnico datumov, ko so se začele in končale različne faze projekta, kot so delo na terenu (glede na različne načine zbiranja podatkov), opomniki in spremljanje, preverjanje in urejanje podatkov, nadaljnje potrjevanje in imputiranje, raziskovanje neodgovorov (po potrebi) in ocene ter pošiljanje podatkov Eurostatu in izkazovanje nacionalnih rezultatov.
This covers the type of results sent to enterprises, a dissemination scheme of results and a copy of any methodological documents about the statistics provided.
To vključuje vrsto rezultatov, ki so bili poslani podjetjem, shemo izkazovanja rezultatov in izvode vseh metodoloških dokumentov o predloženih statističnih podatkih.
This covers the deviations from the standard European questionnaire and definitions provided in the manual referred to in Article 8 and a description of links done with other statistical sources (use of certain data available in registers, survey linked to another national survey).
To vključuje odstopanja od standardnega evropskega vprašalnika in opredelitev v priročniku iz člena 8 ter opis povezav z drugimi statističnimi viri (uporaba nekaterih podatkov, ki so na voljo v registrih, raziskovanje, povezano z drugim nacionalnim raziskovanjem).
This covers a comparison of statistics for the same phenomenon or item from other surveys or sources and an assessment of coherence with structural business statistics for the number of persons employed as a function of NACE Rev. 2 and size classes.
To vključuje primerjavo statističnih podatkov o istem pojavu ali spremenljivki, pridobljenih iz drugih raziskovanj ali virov, in oceno skladnosti s strukturno statistiko podjetij za število zaposlenih, izraženo kot funkcija skupine dejavnosti NACE Rev.
Number of persons employed from structural business statistics and number of persons employed from CVTS.
2 in velikostnega razreda.
Percentage of differences (SBS — CVTS)/SBS.
število zaposlenih po strukturni statistiki podjetij in število zaposlenih po raziskovanju NPU,
COST AND BURDEN
odstotek razlik (strukturna statistika podjetij – raziskovanje NPU)/strukturna statistika podjetij.
This covers an analysis of the burden and benefit at national level through, for example, a consideration of average time for answering the questionnaire, problematic questions and variables, variables most/least useful in describing CVT at national level, estimated or actual satisfaction level of data users at national level, difference of burden between small and large enterprises and efforts made to reduce the burden.’
STROŠKI IN OBREMENITEV
The coefficient of variation is the ratio of the square root of the variance of the estimator to the expected value.
To vključuje analizo obremenitve in koristi na nacionalni ravni, na primer ob upoštevanju povprečnega časa odgovora na vprašalnik, težavnih vprašanj in spremenljivk, spremenljivk, ki se največ/najmanj uporabljajo pri opisu NPU na nacionalni ravni, ocenjene ali dejanske ravni zadovoljstva uporabnikov podatkov na nacionalni ravni, različne obremenitve za mala in velika podjetja ter prizadevanj za zmanjšanje obremenitve.“
It is estimated by the ratio of the square root of the estimate of the sampling variance to the estimated value.
Koeficient variacije je razmerje med kvadratnim korenom variance cenilke in pričakovano vrednostjo.
The estimation of the sampling variance must take into account the sampling design and changes of strata.
Ocenjuje se z razmerjem med kvadratnim korenom ocene variance vzorčenja in pričakovano vrednostjo.
The unit response rate is the ratio of the number of in scope respondents to the number of questionnaires sent to the population selected.
Ocena variance vzorčenja mora upoštevati načrt vzorčenja in spremembe stratumov.
The item response rate for a variable is the ratio of the number of available data to the number of available and missing data (equal to the number of in scope respondents).
Delež odgovorov enot je razmerje med številom poročevalcev v opazovanju in številom vprašalnikov, poslanih izbrani populaciji.
CVT stands for continuing vocational training.
Delež odgovorov spremenljivke je razmerje med številom razpoložljivih podatkov in številom razpoložljivih in manjkajočih podatkov (enako številu poročevalcev v opazovanju).
IVT stands for initial vocational training.
NPU pomeni nadaljevalno poklicno usposabljanje.
Two decimal positions — use “.” as decimal separator
Ponderacijski faktor.
A2m
Dve decimalni mesti – kot decimalno ločilo uporabite ‚.‘
Commission Regulation (EU) No 1154/2014
Uredba Komisije (EU) št. 1154/2014
refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health
o zavrnitvi odobritve nekaterih zdravstvenih trditev na živilih, razen tistih, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok
Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods [1], and in particular Article 18(5) thereof,
ob upoštevanju Uredbe (ES) št. 1924/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o prehranskih in zdravstvenih trditvah na živilih [1] in zlasti člena 18(5) Uredbe,
Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State.
Uredba (ES) št. 1924/2006 določa tudi, da lahko nosilci živilske dejavnosti vloge za odobritev zdravstvenih trditev predložijo pristojnemu nacionalnemu organu države članice.
The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as ‘the Authority’, for a scientific assessment, as well as to the Commission and the Member States for information.
Pristojni nacionalni organ veljavne vloge pošlje Evropski agenciji za varnost hrane (v nadaljnjem besedilu: Agencija) za pripravo znanstvene ocene ter Komisiji in državam članicam v vednost.
Following an application from EJP Pharmaceutical ApS, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of zinc and prevention of bad breath (Question No EFSA-Q-2010-01092) [2].
Družba EJP Pharmaceutical ApS je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi cinka na preprečevanje ustnega zadaha (vprašanje št.
The claim proposed by the applicant was worded as follows:
EFSA-Q-2010-01092) [2].
‘Prevents bad breath by neutralising of volatile sulphur compounds (VSC) in the mouth and oral cavity’.
Vložnik je predlagal naslednjo trditev:
On 1 June 2011, the Commission and the Member States received the scientific opinion, from the Authority, which concluded that the claim ‘prevents bad breath by neutralising of volatile sulphur compounds in the mouth and oral cavity’ is related to breath odour rather than to a function of the body as required by Article 13 of Regulation (EC) No 1924/2006.
„Preprečuje ustni zadah z nevtralizacijo hlapnih žveplovih spojin v ustih in ustni votlini.“
During the evaluation of the claim, the applicant was requested to clarify how the proposed claim is linked to a function of the body.
Komisija in države članice so 1. junija 2011 prejele znanstveno mnenje Agencije, ki je ugotovila, da je trditev „preprečuje ustni zadah z nevtralizacijo hlapnih žveplovih spojin v ustih in ustni votlini“ povezana z ustnim vonjem in ne s telesno funkcijo, kot je določeno v členu 13 Uredbe (ES) št. 1924/2006.
The applicant argued that the production of volatile sulphur compounds and halitosis as part of the bacterial flora of the mouth and oral cavity is related to the function of the mouth and oral cavity, and thus to a function of the body.
Med postopkom presoje zahtevka je bil vložnik pozvan, naj pojasni, kako je predlagana trditev povezana s telesno funkcijo.
However, the Authority noted that the evidence provided did not demonstrate that the chemical neutralisation of volatile sulphur compounds in the mouth, in order to improve bad breath, constitutes a physiological effect in relation to a function of the body.
Vložnik je trdil, da je tvorjenje hlapnih žveplovih spojin in halitoze kot del bakterijske flore v ustih in ustni votlini povezani s funkcijo ust in ustne votline ter posledično tudi s telesno funkcijo.
Therefore, the applicant did not provide evidence that zinc has a physiological effect in relation to a function of the body as required by Article 13(1)(a) of Regulation (EC) No 1924/2006.
Kljub temu pa je Agencija ugotovila, da predloženi dokazi ne dokazujejo, da kemijska nevtralizacija hlapnih žveplovih spojin v ustih z namenom izboljšanja ustnega zadaha predstavlja fiziološki učinek v povezavi s telesno funkcijo.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Zato vložnik ni predložil dokazov, da ima cink fiziološki učinek v povezavi s telesno funkcijo, kot zahteva člen 13(1)(a) Uredbe (ES) št. 1924/2006.
Following an application from Leiber GmbH, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Yestimun® and defence against pathogens in the upper respiratory tract (Question No EFSA-Q-2012-00761) [3].
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
‘Daily administration of Yestimun® helps to maintain the body's defence against pathogens’.
Družba Leiber GmbH je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki proizvoda Yestimun® in zaščito zgornjih dihalnih poti pred patogeni (vprašanje št.
On 8 April 2013 the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship could not be established between the consumption of Yestimun® ((1,3)-(1,6)-β-D-glucans from brewer's yeast cell wall) and the claimed effect.
EFSA-Q-2012-00761) [3].
Following an application from Vivatech, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Transitech® and improvement of bowel function which is maintained after cessation of consumption of the food (Question No EFSA-Q-2013-00087) [4].
„Dnevni vnos proizvoda Yestimun® pomaga ohranjati zaščito telesa pred patogeni.“
‘Improves transit and durably regulates it’.
Komisija in države članice so 8. aprila 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledične povezave med uživanjem proizvoda Yestimun® ((1,3)-(1,6)-β-D-glukani iz celičnih sten pivskih kvasovk) in navedeno trditvijo ni bilo mogoče utemeljiti.
On 13 June 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Transitech® and the claimed effect.
Družba Vivatech je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki proizvoda Transitech® in izboljšanim delovanjem črevesja, ki se ohranja po končanem uživanju hrane (vprašanje št.
Following an application from Clasado Limited, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Bimuno® GOS and reduction of gastro-intestinal discomfort (Question No EFSA-Q-2012-01007) [5].
EFSA-Q-2013-00087) [4].
‘Regular daily consumption of 1,37 g galacto-oligosaccharides from Bimuno® may reduce abdominal discomfort’.
„Izboljša prehajanje črevesne vsebine in ga trajno ureja.“
On 18 June 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that a health claim on Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006 has already been assessed by the Authority with an unfavourable outcome [6] and that the supplementary information submitted by the applicant did not provide evidence that could be used for the scientific substantiation of this claim.
Komisija in države članice so 13. junija 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem proizvoda Transitech® in navedeno trditvijo ni utemeljena.
Following an application from Fuko Pharma Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactobacillus rhamnosus GG and maintenance of normal defecation during antibiotic treatment (Question No EFSA-Q-2013-00015) [7].
Družba Clasado Limited je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki proizvoda Bimuno® GOS na zmanjšanje prebavnih motenj (vprašanje št.
‘Lactobacillus rhamnosus GG for maintaining normal defecation during oral antibiotic treatment’.
EFSA-Q-2012-01007) [5].
On 18 June 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Lactobacillus rhamnosus GG and the claimed effect.
„Redno dnevno uživanje 1,37 g galakto-oligosaharidov Bimuno® lahko zmanjša prebavne motnje.“
Following an application from Gelita AG, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of VeriSol®P and a change in skin elasticity leading to an improvement in skin function (Question No EFSA-Q-2012-00839) [8].
Komisija in države članice so 18. junija 2013 prejele znanstveno mnenje Agencije, ki je ugotovila, da je zdravstveno trditev glede proizvoda Bimuno® GOS in zmanjšanja prebavnih motenj v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 že obravnavala z negativnim izidom [6] in da dodatni podatki, ki jih je predložil vložnik, ne služijo kot dokaz za znanstveno utemeljitev te trditve.
‘Characteristic collagen peptide mixture (collagen hydrolysate) having a beneficial physiological effect on the maintenance of skin health, as indicated by an increased skin elasticity and a reduction of wrinkles volume, by contributing to a normal collagen and elastin synthesis’.
Družba Fuko Pharma Ltd je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Lactobacillus rhamnosus GG na ohranjanje normalne defekacije med zdravljenjem z antibiotiki (vprašanje št.
On 20 June 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship could not be established between the consumption of Verisol®P and the claimed effect.
EFSA-Q-2013-00015) [7].
Following an application from Pharmatoka S.A.S., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of proanthocyanidins in Urell® and the reduction of bacterial colonisation of the urinary tract (Question No EFSA-Q-2012-00700) [9].
„Lactobacillus rhamnosus GG za ohranjanje normalne defekacije med peroralnim zdravljenjem z antibiotiki.“
The claim proposed by the applicant was worded, inter alia, as follows:
Komisija in države članice so 18. junija 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem Lactobacillus rhamnosus GG in navedeno trditvijo ni utemeljena.
‘Proanthocyanidins from Urell® contribute to support defence against bacterial pathogens in the lower urinary tract’.
Družba Gelita AG je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki proizvoda VeriSol®P in spremembo elastičnosti kože, ki izboljša delovanje kože (vprašanje št.
On 26 July 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship could not be established between the consumption of proanthocyanidins in Urell® and the claimed effect.
EFSA-Q-2012-00839) [8].
Following an application from the Institute of Cellular Pharmacology (ICP) Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Preservation® and rapid recovery of cellular activity post stress (Question No EFSA-Q-2013-00021) [10].
„Značilna mešanica kolagena in peptidov (kolagenski hidrolizat), ki ima pozitiven fiziološki učinek na ohranjanje zdravja kože, kar se kaže v povečani elastičnosti kože in zmanjšanju števila gub, tako da prispeva k normalni sintezi elastina in kolagena.“